炭疽芽孢杆菌体外抗菌药物敏感性试验的系统综述,1947-2019年
该综述检索同行评议文献,汇总采用标准化方案对炭疽芽孢杆菌进行体外抗菌药物敏感性试验的出版物,分析所报告的最低抑菌浓度。文献中大多数分离株对当前推荐用于暴露后预防和治疗的一线抗菌药物敏感,潜在替代药物的数据可用于出现显著耐药、菌株经生物工程改造或一线药物不耐受或不可及的情况。
要点
- 大多数炭疽芽孢杆菌分离株对当前推荐用于暴露后预防和治疗的一线抗菌药物敏感。
- 潜在替代抗菌药物的数据可用于一线药物耐药、菌株经生物工程改造或一线药物不耐受或不可及的情况。
- 综述汇总了采用标准化方案、针对美国食品药品监督管理局批准且有市售的抗菌药物的敏感性试验出版物。
核心结论
- 文献中大多数炭疽芽孢杆菌分离株对当前推荐用于暴露后预防和治疗的一线抗菌药物敏感。
- 潜在替代抗菌药物的数据可用于出现显著耐药、菌株经生物工程改造或一线抗菌药物不耐受或不可及的情况。
研究设计与样本
- 系统综述,检索同行评议文献中所有详细报道炭疽芽孢杆菌抗菌药物敏感性试验的出版物。
- 在发现的文献中,汇总了采用标准化方案、针对美国食品药品监督管理局批准且有市售的抗菌药物进行敏感性试验的出版物子集。
- 分析所发现文献的结果,包括所报告的最低抑菌浓度。
主要发现
- 文献中大多数炭疽芽孢杆菌分离株对当前推荐用于暴露后预防和治疗的一线抗菌药物敏感。
- 所分析的出版物报告了最低抑菌浓度。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bacillus anthracis, the causative agent of anthrax, is a high-consequence bacterial pathogen that occurs naturally in many parts of the world and is considered an agent of biowarfare or bioterrorism. Understanding antimicrobial susceptibility profiles of B. anthracis isolates is foundational to treating naturally occurring outbreaks and to public health preparedness in the event of an intentional release. In this systematic review, we searched the peer-reviewed literature for all publications detailing antimicrobial susceptibility testing of B. anthracis. Within the set of discovered articles, we collated a subset of publications detailing susceptibility testing that followed standardized protocols for Food and Drug Administration-approved, commercially available antimicrobials. We analyzed the findings from the discovered articles, including the reported minimal inhibitory concentrations. Across the literature, most B. anthracis isolates were reported as susceptible to current first-line antimicrobials recommended for postexposure prophylaxis and treatment. The data presented for potential alternative antimicrobials will be of use if significant resistance to first-line antimicrobials arises, the strain is bioengineered, or first-line antimicrobials are not tolerated or available.
引用
- Maxson T, Kongphet-Tran T, Mongkolrattanothai T, et al. Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019. Clin Infect Dis. 2022. PMID: 36251548. doi:10.1093/cid/ciac520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。